Manorama IndustriesNSE:MANORAMA
Current view Q1 2027
Makes speciality cocoa-butter-equivalent and shea-based fats for chocolate and cosmetics. Revenue and margins both keep climbing as capacity utilisation fills up, and management has delivered every guidance so far. But the earnings trigger has already played out and the business is running at peak performance - the next leg, a new product line plus capacity expansion, is an FY28 story.
Latest exchange filings last 5 · 5 after Q1 2027
- 4 Sep ’26Board approved Dr. Rohini Tiwari’s appointment and up to ₹75 crore infusion in six foreign subsidiaries. ↗
- 4 Sep ’26Board approved Dr. Rohini Tiwari’s appointment and up to ₹75 crore infusion into six overseas subsidiaries. ↗
- 28 Aug ’26Newspaper Publication for dispatch of Notice of 21st Annual General Meeting along with Annual report for the Financial Year 2025-26. ↗
- 27 Aug ’26Reg. 34 (1) Annual Report. 27 Aug ↗
- 27 Aug ’26Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company/RTA/Depository Participants. 27 Aug ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q1 2027
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q1 2027
| Metric | This year vs lastYoY · vs Q1 2026 | vs the quarter beforeQoQ, sequential · vs Q4 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +39.3% | +5.8% | +57.0% | +46.2% |
| Operating profit | ▲ +38.0% | +5.8% | +82.8% | +56.0% |
| EPS | ▲ +61.1% | +37.0% | +98.4% | +71.7% |
| PAT | ▲ +60.8% | +36.7% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +39.3%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Strong78/100
Growing fast — and the market has noticed. Profit per share grew 60% a year, and buyers now pay more for each rupee of it than they did a year ago. Some of the re-pricing has already happened.
₹1,865 → ₹3,730 needs the P/E at 21× — it is 42× today. The rest would come from earnings growing as they have.
At ₹2,783 the price-tag on its earnings reaches the 63× it is being projected toward — the point where being cheap against that yardstick is used up.
Both engines fired — but you're buying after the re-rate.
How this is calculated
This is arithmetic, not a forecast — Return = ΔEPS × ΔMultiple. It says what would have to be true, not how likely it is, and "earnings keep growing at this rate for three more years" is the assumption doing the most work. There is no 5-year range on file for this company, so the comparison falls back to its average alone. This is a mid-cap at ₹12,127 cr, so the odds of a re-rate are not fighting its own size.
Growth rate used: 60.0% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR, capped at 60%. Latest quarter reads 60%.
How it compares with its rivals Food Products · 6 of 28 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Manorama Indust. | ₹1,968 | 47.0× | ₹12,419 Cr | 35.4% | +61.3% | +39.5% |
| EID Parry | ₹689 | 15.1× | ₹12,261 Cr | 17.0% | −42.5% | +3.4% |
| Orkla India | ₹579 | 26.0× | ₹7,936 Cr | 14.9% | +9.7% | +10.4% |
| Krishival Foods | ₹412 | 53.2× | ₹1,171 Cr | 16.2% | +12.4% | +79.6% |
| Shri Ahimsa | ₹473 | 36.8× | ₹1,108 Cr | 23.0% | +24.4% | +14.0% |
| Freshara Agro | ₹446 | 28.3× | ₹1,048 Cr | — | — | — |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | yes — widening, and steadily | operating margin 17% → 27% over 3 years |
|---|---|---|
| Did the profit turn into cash? | very little of it arrived as cash | 93% last year, -37% over three · free cash flow ₹206 cr, positive in 2 of 5 years |
| Is the growth borrowed? | borrowed about as much as it owns | ₹355 cr — 0.51× its own equity (was 1.04×) |
| Is it being collected? | customers are paying faster | 15 days to collect, down 33 in a year · cash cycle 331 days |
| Who has been buying? | the promoters have held steady | promoters 54.3% (−0.1 in a year), 57.3% → 54.3% over 2.8 years · FIIs 3.2% (−0.2) · DIIs 2.6% (−2.0) · shareholders 6,712 → 33,841 |
| What does it earn on its capital? | earns a high return on the capital it employs | ROCE 35.4% · ROE 40.2% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
In its favour
- Company has reduced debt.
- Company is expected to give good quarter
- Company has delivered good profit growth of 74.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.7%
- Debtor days have improved from 32.2 to 15.1 days.
- Company's median sales growth is 34.0% of last 10 years
Against it
- Stock is trading at 16.9 times its book value
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.